Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07524634) titled 'Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis' on April 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Case Comprehensive Cancer Center
Condition:
Amyloid Light-chain Amyloidosis
Intervention:
Drug: BCMA bispecific
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 2026
Target Sample Size: 64
Countries of Recruitment:
United States
To know more, visit https://...